CSIMarket
 
Legend Biotech Corporation  (NASDAQ: LEGN)
Other Ticker:  
 
 
Price: $37.7700 $-0.07 -0.185%
Day's High: $39.33 Week Perf: 1.48 %
Day's Low: $ 37.59 30 Day Perf: 5.56 %
Volume (M): 1,359 52 Wk High: $ 70.13
Volume (M$): $ 51,326 52 Wk Avg: $48.02
Open: $37.83 52 Wk Low: $30.17



 Market Capitalization (Millions $) 13,316
 Shares Outstanding (Millions) 353
 Employees 800
 Revenues (TTM) (Millions $) 285
 Net Income (TTM) (Millions $) -518
 Cash Flow (TTM) (Millions $) 786
 Capital Exp. (TTM) (Millions $) 20

Legend Biotech Corporation
Legend Biotech Corporation is a biotechnology company that focuses on discovering and developing innovative cell therapy treatments for patients with cancer. The company was established in 2014 as a joint venture between Genscript Biotech Corporation and Janssen Biotech, Inc., and is headquartered in Somerset, New Jersey, USA, with additional facilities in China.

The company's main focus is on the development of chimeric antigen receptor (CAR) T cell therapies, a type of immunotherapy that involves genetically modifying a patient's own immune cells to recognize and target cancer cells. Legend Biotech's lead product candidate is LCAR-B38M, a CAR T therapy that targets the B-cell maturation antigen (BCMA) and is being developed for the treatment of multiple myeloma.

LCAR-B38M has shown promising results in early-phase clinical trials, with high response rates and durable remissions in patients with relapsed/refractory multiple myeloma. The therapy has also demonstrated a favorable safety profile, with no severe toxicities observed in clinical trials.

In addition to LCAR-B38M, Legend Biotech is also developing other CAR T therapies targeting different cancer antigens, including CD20 and CD2 The company is also exploring the potential of other cell-based therapies, including TCR T cell therapies and CAR NK cell therapies.

Legend Biotech has a strong research and development team, with expertise in cell biology, immunology, and oncology. The company has collaborations with academic and industry partners, including the University of Pennsylvania, Tmunity Therapeutics, and Janssen Biotech, to advance its pipeline of cell therapies.

In 2019, Legend Biotech became a public company through an initial public offering (IPO) on the NASDAQ Global Select Market, raising $424 million in gross proceeds. The company's leadership team includes Frank Fan, CEO, Dr. Fang Zhou, President and Chief Scientific Officer, and Mr. Eric Zhang, Chief Financial Officer.

Overall, Legend Biotech is a promising biotechnology company that is focused on developing innovative cell therapies to treat cancer. With a strong pipeline of products and a talented R&D team, the company is well-positioned to make significant contributions to the field of cancer immunotherapy.


   Company Address: Legend Biotech Corporation Somerset 8873 NJ
   Company Phone Number: 317-5050   Stock Exchange / Ticker: NASDAQ LEGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        4.91% 
AZN   -0.43%    
JNJ        0.87% 
MRK   -10.92%    
NVS        4.83% 
SNY   -1.29%    
• View Complete Report
   



Clinical Study

Abstract The CARTITUDE-4 clinical trial data, conducted by Legend Biotech, highlights the efficacy of CAR...

Published Tue, Dec 10 2024 12:35 AM UTC

CARVYKTI s Impact on Minimal Residual Disease and Overall Survival in Multiple Myeloma: Insights from the CARTITUDE-4 Trial Abstract : The CARTITUDE-4 clinical trial data, conducted by Legend Biotech, highlights the efficacy of CARVYKTI (ciltacabtagene autoleucel) in treating relapsed or lenalidomide-refractory multiple myeloma. The findings demonstrate significant improvem...

Clinical Study

Evolving Multiple Myeloma Treatment Findings from the CARTITUDE-4 Trial Reveal Promising Outcomes

Published Tue, Nov 5 2024 2:10 PM UTC

Revolutionizing Multiple Myeloma Treatment: Findings from the CARTITUDE-4 Trial Reveal Promising OutcomesMultiple myeloma, a malignancy of plasma cells in bone marrow, remains a formidable adversary in oncology, presenting challenges in treatment due to its recurrent nature. Traditional therapies have improved survival rates, but many patients experience relapse or become r...

Management Changes

Legend Biotech Appoints Alan Bash as President of CARVYKTI

Published Mon, Nov 4 2024 12:31 PM UTC

Legend Biotech?s Strategic Appointments and Innovations in Cell TherapyIntroductionIn a rapidly transforming pharmaceutical landscape, Legend Biotech Corporation is making significant strides to solidify its position as a leader in cell therapy. Recent developments have highlighted both the challenges the company faces in terms of financial performance and the proactive me...

Economy

Expanding Horizons Legend Biotechs Commitment to Advancing Cell Therapy Research with a New Facility in Philadelphia

Published Thu, Oct 3 2024 11:30 AM UTC

The landscape of pharmaceutical sciences is rapidly evolving, particularly in the field of cell therapy. Advances in technology and significant investment in research and development are crucial for maintaining leadership in this innovative field. In this context, Legend Biotech has announced the establishment of a new, state-of-the-art cell therapy research and development ...

Clinical Study

CARVYKTI Delivers Unmatched Survival Benefit for Multiple Myeloma Groundbreaking Results from the CARTITU...

Published Fri, Sep 27 2024 8:35 PM UTC

Multiple myeloma (MM) poses a significant clinical challenge, particularly when patients have relapsed or have become refractory to lenalidomide, a cornerstone in MM treatment. Current standard therapies include combinations such as pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd). However, their effectiveness diminishes...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com